A Federal Court Rejects the Drug Industry's Challenge to Medicare Price Negotiation

A federal appeals court ruled against a lawsuit brought by pharmaceutical industry representatives challenging Medicare’s drug price negotiation program. The court found that drugmakers are not entitled to sell their products to Medicare at a price of their choosing. The decision leaves the negotiation framework intact.